CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential…

Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF

CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical research; Companies amend existing drug…

Fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 300 peer-reviewed publications, and 48 pharma collaborations

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 2, 2024 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the…

Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs)

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, February 29, 2024 (GLOBE NEWSWIRE) – CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential…

Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 28, 2024 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential…

Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads